Sibutramine artificial antigen, preparation method and application thereof, sibutramine polyclonal antibody and sibutramine detection kit
By preparing sibutramine artificial antigen coupled to carrier protein, artificial antibodies with high sensitivity and high specificity are obtained for use in sibutramine detection kits, which solves the problems of high detection cost and complex operation in the prior art. Fast and accurate sibutramine detection is achieved.
Patent Information
- Application Number
- CN202411172594.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art lacks antibodies that can detect sibutramine with high sensitivity and specificity, resulting in high detection costs, complex operation and unsuitable for rapid on-site large-scale detection.
By preparing sibutramine artificial antigen coupled to carrier protein, artificial antibodies with high sensitivity and specificity are obtained, and applied to sibutramine detection kits to achieve fast and accurate detection.
It provides artificial antibodies and detection kits with high sensitivity and specificity, which solves the problems of high detection costs and complex operation. It is suitable for large-scale and rapid on-site inspections and meets the testing needs of consumers, enterprises and regulatory departments.
Smart Images

Figure CN119019534A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of food safety detection, and in particular to a sibutramine artificial antigen and a preparation method and application thereof, a sibutramine polyclonal antibody, and a sibutramine detection kit. Background Art
[0002] Sibutramine, chemically known as N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethylamine, is a drug used for the long-term treatment of obesity. As a norepinephrine inhibitor, the drug plays a role in weight loss by inhibiting nerve centers and reducing appetite. As time goes by, the safety and side effects of sibutramine have gradually attracted people's attention. The European Committee for Medicinal Products for Human Use recommended suspending the sale and use of all weight loss drugs containing sibutramine in the EU; the US Food and Drug Administration also announced a ban on the sale and use of sibutramine; my country's Food and Drug Administration also required the country to stop the production, sale and use of sibutramine preparations and raw materials.
[0003] However, due to the obvious weight loss effect of sibutramine and its low cost, some unscrupulous vendors will add sibutramine to drinks with weight loss effects such as apple cider vinegar and coffee to enhance their weight loss effects and make them popular with more consumers. Therefore, it is necessary to establish a method to detect the content of sibutramine.
[0004] At present, the detection methods of sibutramine mainly include thin layer chromatography, high performance liquid chromatography, mass spectrometry and high performance liquid chromatography-mass spectrometry and other instrumental analysis methods. Although these methods can accurately detect the analyte, the instruments and equipment are expensive, the sample pretreatment is complicated and cumbersome, the detection cost is high, and professional personnel are required to operate, which is only suitable for laboratory scientific research. Immunoassay represented by enzyme-linked immunosorbent assay (ELISA) has the advantages of simple operation, low detection cost and fast detection speed. It is suitable for on-site large-scale rapid detection of samples and can better meet the detection work of consumers, enterprises and regulatory authorities.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] One of the purposes of the present invention is to provide an artificial sibutramine antigen, and the sibutramine polyclonal antibody prepared from the artificial antigen has both high sensitivity and high specificity.
[0007] The second object of the present invention is to provide a method for preparing an artificial sibutramine antigen, which has a simple process, high efficiency and high success rate.
[0008] The third object of the present invention is to provide an application of sibutramine artificial antigen, which is conducive to the preparation of sibutramine polyclonal antibodies with high sensitivity and good specificity.
[0009] The fourth object of the present invention is to provide a sibutramine polyclonal antibody, which has the advantages of high sensitivity and good specificity, and provides a core raw material for establishing a high-sensitivity sibutramine immunoassay method.
[0010] The fifth object of the present invention is to provide an application of a sibutramine polyclonal antibody, which solves the technical problem in the prior art of lacking antibodies that can detect sibutramine with high sensitivity and high specificity.
[0011] The sixth object of the present invention is to provide a sibutramine detection kit having the advantages of high sensitivity and good specificity.
[0012] The seventh object of the present invention is to provide an application of a sibutramine detection kit, which solves the technical problem in the prior art of lacking antibodies that can detect sibutramine with high sensitivity and high specificity.
[0013] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:
[0014] In a first aspect, an artificial sibutramine antigen is obtained by coupling 1-(4-phenol)cyclobutylamine with a carrier protein.
[0015] Furthermore, the carrier protein includes at least one of bovine serum albumin and chicken ovalbumin.
[0016] In a second aspect, a method for preparing the sibutramine artificial antigen described in any one of the above items comprises the following steps:
[0017] The reaction solution of 1-(4-phenol)cyclobutylamine is added to the carrier protein solution, reacted in a dark environment, and then dialyzed to obtain the sibutramine artificial antigen.
[0018] Further, the preparation method of the reaction solution of 1-(4-phenol)cyclobutylamine comprises the following steps:
[0019] 1-(4-phenol)cyclobutylamine, 5-hydroxytryptamine, N-carbonylsuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide are dissolved in N,N-dimethylamide respectively, mixed and reacted in a dark environment to obtain the reaction solution of 1-(4-phenol)cyclobutylamine.
[0020] Furthermore, the method for preparing the carrier protein solution comprises the following steps:
[0021] The carrier protein is added into the coating buffer to obtain the carrier protein solution.
[0022] In a third aspect, a use of the artificial sibutramine antigen described in any one of the above items in the preparation of sibutramine antibodies.
[0023] In a fourth aspect, a sibutramine polyclonal antibody is obtained by immunizing an animal with any of the above-mentioned sibutramine artificial antigens.
[0024] A fifth aspect provides an application of the above-mentioned sibutramine polyclonal antibody in a sibutramine immunoassay method.
[0025] A sixth aspect provides a sibutramine detection kit, the kit comprising the sibutramine polyclonal antibody described above.
[0026] A seventh aspect provides an application of the above-mentioned sibutramine detection kit in a sibutramine immunoassay method.
[0027] Compared with the prior art, the present invention has at least the following beneficial effects:
[0028] The artificial sibutramine antigen provided by the present invention is more similar to 5-hydroxytryptamine in spatial structure, so the sibutramine polyclonal antibody obtained from the artificial antigen has not only high sensitivity but also good specificity.
[0029] The method for preparing the sibutramine artificial antigen provided by the invention has simple process, high efficiency and high success rate.
[0030] The application of the sibutramine artificial antigen provided by the present invention is conducive to the preparation of sibutramine polyclonal antibodies with high sensitivity and good specificity.
[0031] The sibutramine polyclonal antibody provided by the present invention has the advantages of high sensitivity and good specificity, and provides a core raw material for establishing a high-sensitivity sibutramine immunoassay method.
[0032] The application of the sibutramine polyclonal antibody provided by the present invention solves the technical problem in the prior art of lacking antibodies capable of detecting sibutramine with high sensitivity and high specificity.
[0033] The sibutramine detection kit provided by the present invention has the advantages of high sensitivity and good specificity.
[0034] The application of the sibutramine detection kit provided by the present invention solves the technical problem of the lack of antibodies capable of detecting sibutramine with high sensitivity and high specificity in the prior art. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0036] Figure 1 A flow chart for preparing a sibutramine polyclonal antibody provided in one embodiment of the present invention;
[0037] Figure 2 The ultraviolet scanning identification curve of the artificial antigen provided in Example 1 of the present invention;
[0038] Figure 3 The ultraviolet scanning identification curve of the artificial antigen provided in Example 1 of the present invention;
[0039] Figure 4 This is the standard curve of the indirect competitive ELISA of heterologous coating of sibutramine polyclonal antibody provided in Example 3 of the present invention. DETAILED DESCRIPTION
[0040] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0041] According to the first aspect of the present invention, there is provided an artificial sibutramine antigen obtained by coupling 1-(4-phenol)cyclobutylamine with a carrier protein.
[0042] It should be noted that, for the ELISA detection method of sibutramine, most of the antibodies are currently prepared using didesmethyl sibutramine as a hapten; the present invention takes the weight loss mechanism of sibutramine as the starting point, because the weight loss mechanism of sibutramine lies in that its metabolites can occupy the binding sites of 5-hydroxytryptamine reuptake protein and 5-hydroxytryptamine in the synaptic cleft to inhibit the reuptake of 5-hydroxytryptamine by the presynaptic membrane of the nerve, causing the body to produce a sense of fullness and increase heat production, thereby achieving the purpose of weight loss. Therefore, the present invention reduces steric hindrance by removing groups such as 2-methylpropyl of sibutramine to form 1-(4-phenol)cyclobutylamine, so that its spatial structure fits 5-hydroxytryptamine as much as possible, thereby improving the specificity of the corresponding antibody.
[0043] In summary, the artificial sibutramine antigen provided by the present invention is more similar to 5-hydroxytryptamine in spatial structure, so the sibutramine polyclonal antibody obtained from the artificial antigen has not only high sensitivity but also good specificity.
[0044] In a preferred embodiment, the carrier protein includes but is not limited to at least one of bovine serum albumin (BSA) and chicken ovalbumin (OVA).
[0045] According to a second aspect of the present invention, there is provided a method for preparing the sibutramine artificial antigen described in any one of the above items, comprising the following steps:
[0046] The reaction solution of 1-(4-phenol)cyclobutylamine was added to the carrier protein solution, and the reaction was carried out in a dark environment, followed by dialysis to obtain the sibutramine artificial antigen.
[0047] The method for preparing the sibutramine artificial antigen provided by the invention has simple process, high efficiency and high success rate.
[0048] In the present invention, 1-(4-phenol)cyclobutylamine can be coupled with a carrier protein by an active ester method, and then dialyzed to obtain the sibutramine artificial antigen.
[0049] In a preferred embodiment, the method for preparing the reaction solution of 1-(4-phenol)cyclobutylamine comprises the following steps:
[0050] 1-(4-phenol)cyclobutylamine, 5-hydroxytryptamine, N-carbonylsuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide are dissolved in N,N-dimethylamide respectively, mixed and reacted in a dark environment to obtain a reaction solution of 1-(4-phenol)cyclobutylamine.
[0051] The invention couples 1-(4-phenol)cyclobutylamine, 5-hydroxytryptamine and a carrier protein to form an artificial sibutramine antigen.
[0052] In the present invention, the mass volume ratio of 1-(4-phenol)cyclobutanamine, 5-hydroxytryptamine and N,N-dimethylformamide (DMF) can be 0.36 mg:0.18 mg:0.125 mL, but is not limited thereto, which is more conducive to further improving the synthesis effect of sibutramine artificial antigen.
[0053] In the present invention, the mass volume ratio of N-carbonylsuccinimide (NHS) to N,N-dimethylformamide (DMF) can be 5 mg:0.25 mL, but is not limited thereto; the mass volume ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) to N,N-dimethylformamide (DMF) can be 5 mg:0.5 mL, but is not limited thereto.
[0054] In a preferred embodiment, the method for preparing the carrier protein solution comprises the following steps:
[0055] Add the carrier protein (BSA and / or OVA) to the coating buffer to obtain a carrier protein solution; wherein the mass volume ratio of BSA to the coating buffer can be 3 mg:2 mL, but not limited thereto; the mass volume ratio of OVA to the coating buffer can be 2 mg:1 mL, but not limited thereto.
[0056] In the present invention, the formula ratio of the coating buffer may be: 1.69 g sodium carbonate and 2.95 g sodium bicarbonate are diluted to 1 L with distilled water, but is not limited thereto.
[0057] A typical preparation method of sibutramine artificial antigen comprises the following steps:
[0058] S1: 1-(4-phenol)cyclobutylamine, 5-hydroxytryptamine, N-carbonylsuccinimide (NHS) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) are dissolved in N,N-dimethylformamide (DMF) respectively, mixed, and then stirred for reaction at room temperature in the dark for 12 h to 14 h to obtain a reaction solution of 1-(4-phenol)cyclobutylamine;
[0059] S2: adding bovine serum albumin (BSA) and / or chicken ovalbumin (OVA) to the coating buffer to obtain a bovine serum albumin solution and / or a chicken ovalbumin solution;
[0060] S3: slowly dripping the reaction solution of 1-(4-phenol)cyclobutylamine into the bovine serum albumin solution and / or the chicken egg albumin solution, stirring the mixture at room temperature in the dark for 3 hours to obtain a mixed solution;
[0061] S4: dialyzing the mixed solution obtained in step S3, wherein the dialysate used for the dialysis can be a 0.85% sodium chloride solution, the dialysis time can be three days, and the dialysis can be performed four times a day, so as to obtain the sibutramine artificial antigen.
[0062] In summary, the preparation method provided by the present invention, under the coordinated cooperation of various steps and process parameters, can fully react with each other, thereby effectively synthesizing sibutramine artificial antigen.
[0063] According to the third aspect of the present invention, there is provided a use of any of the above-mentioned artificial sibutramine antigens in the preparation of sibutramine antibodies.
[0064] The application of the sibutramine artificial antigen provided by the present invention is conducive to the preparation of sibutramine polyclonal antibodies with high sensitivity and good specificity.
[0065] According to a fourth aspect of the present invention, there is provided a sibutramine polyclonal antibody obtained by immunizing an animal with any of the above-mentioned sibutramine artificial antigens.
[0066] In the present invention, sibutramine polyclonal antibodies can be obtained by immunizing rabbits with the sibutramine artificial antigen. Specifically, the artificial antigen is emulsified and then immunized with rabbits, and then the rabbit serum is separated and purified. The serum can be purified by the caprylic acid-ammonium sulfate method to obtain polyclonal antibodies.
[0067] A typical preparation method of sibutramine polyclonal antibody, see Figure 1 , including the following steps:
[0068] The artificial sibutramine antigen solution was mixed with an equal amount of adjuvant and emulsified before immunization with New Zealand white rabbits. The initial immunization was mixed with Freund's complete adjuvant and emulsified before immunization. The subsequent booster immunization used the immunogen emulsified with Freund's incomplete adjuvant and then immunized. The immunization was repeated four times, each time with an interval of 3 weeks. The dose for each immunization was 720 μL per rabbit. Blood was collected on the tenth day after the fourth immunization and purified using the caprylic acid-ammonium sulfate method to obtain sibutramine polyclonal antibodies.
[0069] The sibutramine polyclonal antibody provided by the present invention has the advantages of high sensitivity and good specificity, and provides a core raw material for establishing a high-sensitivity sibutramine immunoassay method.
[0070] According to a fifth aspect of the present invention, there is provided a use of the above-mentioned sibutramine polyclonal antibody in a sibutramine immunoassay method.
[0071] The application of the sibutramine polyclonal antibody provided by the present invention solves the technical problem in the prior art of lacking antibodies capable of detecting sibutramine with high sensitivity and high specificity.
[0072] According to a sixth aspect of the present invention, a sibutramine detection kit is provided, the kit comprising the above-mentioned sibutramine polyclonal antibody.
[0073] The sibutramine detection kit provided by the present invention has the advantages of high sensitivity and good specificity.
[0074] According to a seventh aspect of the present invention, there is provided a use of the above-mentioned sibutramine detection kit in a sibutramine immunoassay method.
[0075] The application of the sibutramine detection kit provided by the present invention solves the technical problem of the lack of antibodies capable of detecting sibutramine with high sensitivity and high specificity in the prior art.
[0076] The present invention is further described below by way of examples. Unless otherwise specified, the materials in the examples are prepared according to existing methods or directly purchased from the market.
[0077] Example 1 Synthesis and Identification of Sibutramine Artificial Antigen
[0078] Synthesis method of artificial antigens:
[0079] (1) 0.36 mg of 1-(4-phenol)cyclobutaneamine and 0.18 mg of 5-hydroxytryptamine were dissolved in 0.125 mL of DMF, 5 mg of NHS was dissolved in 0.25 mL of DMF, and 5 mg of EDC was dissolved in 0.5 mL of DMF. The above solutions were mixed and stirred at 16°C in the dark overnight, then centrifuged at 4°C and 6000 r / min for 8 min, and the supernatant was collected;
[0080] (2) Dissolve 3 mg of BSA in 2 mL of coating buffer and 2 mg of OVA in 1 mL of coating buffer to obtain a carrier protein solution;
[0081] (3) 0.15 mL and 0.1 mL of the supernatant were slowly added to the carrier protein solution, respectively, and stirred for reaction at room temperature in the dark for 3 h to obtain a mixed solution;
[0082] (4) The mixed solution was dialyzed against 0.85% sodium chloride solution for 3 days (dialysis solution was changed every 12 hours), and the volume was adjusted to 3 mL with coating buffer to obtain the immunogen 1-(4-phenol)cyclobutanamine-BSA; the volume was adjusted to 2 mL with coating buffer to obtain the coating originals 1-(4-phenol)cyclobutanamine-OVA and 5-hydroxytryptamine-OVA;
[0083] Coating buffer formula: 1.69 g sodium carbonate and 2.95 g sodium bicarbonate are diluted to 1 L with distilled water.
[0084] Identification of artificial antigens:
[0085] Take the above-synthesized artificial antigen for UV scanning, the result is as follows Figure 2 and Figure 3 As shown;
[0086] BSA, OVA and artificial antigens were respectively identified by UV scanning (200nm-400nm), and the maximum absorbance values of each substance before and after coupling were compared. It was found that the absorption curve of sibutramine artificial antigen was significantly different from that of the carrier protein, indicating that sibutramine hapten was successfully coupled with BSA to produce artificial antigen.
[0087] Example 2 Preparation of Sibutramine Polyclonal Antibodies
[0088] immunity:
[0089] New Zealand white rabbits were used for immunization. The immunogen was 1-(4-phenol)cyclobutylamine-BSA. During the initial immunization, the immunogen was emulsified with Freund's complete adjuvant at a volume ratio of 1:1, and then the rabbits were immunized. The immunogen was then emulsified with Freund's incomplete adjuvant at a volume ratio of 1:1. Booster immunizations were performed every three weeks, for a total of three booster immunizations. Rabbit serum was collected one week after the third booster immunization.
[0090] Purification (octanoic acid-ammonium sulfate method):
[0091] (1) Take rabbit serum and centrifuge it at 12000 r / min for 15 min at 4°C to remove the precipitate;
[0092] (2) 1 volume of the supernatant was mixed with 2 volumes of acetate buffer, the pH was adjusted to 4.8, and octanoic acid was added dropwise at room temperature while stirring, with the amount used being 75 μL octanoic acid / mL rabbit serum;
[0093] (3) Stirring the mixture at room temperature for 30 min, and then letting it stand at 4 °C for 2 h;
[0094] (4) Centrifuge at 4°C and 12,000 rpm for 15 min, and filter the supernatant through a sand core funnel or a 125 μm nylon mesh;
[0095] (5) Add 1 / 10 volume of PBS buffer (0.1 M, pH 7.4), adjust the pH to 7.4 with 2 M sodium hydroxide, and calculate the total solution volume;
[0096] (6) Add 0.28 g / mL ammonium sulfate within 30 min under ice bath to make a 45% saturated solution;
[0097] (7) Incubate at 4°C for 1 h, centrifuge at 4°C and 12,000 rpm for 15 min, and discard the supernatant;
[0098] (8) The precipitate was dialyzed against PBS buffer (0.1 M, pH 7.4) for three days to obtain sibutramine polyclonal antibodies.
[0099] Example 3 ELISA detection of sibutramine polyclonal antibodies
[0100] ELISA test method:
[0101] (1) Dilute the original 5-HT-OVA to 1 μg / mL with coating buffer, coat the ELISA plate, add 100 μL to each well, incubate overnight at 37°C, discard the coating buffer, and wash twice;
[0102] (2) Add 120 μL of blocking solution (5% skim milk powder) to each well and block at 37°C for 3 h. Discard the blocking solution, clap the plate, and dry it at 37°C for later use.
[0103] (3) Two groups were prepared for each antibody. Antibody serum diluted from 1K to 64K was added to each row of the ELISA plate in sequence. 50 μL of PBST was added to each well of the titer group, and 50 μL of sibutramine standard diluted to 1 μg / mL with PBST was added to each well of the inhibition group. The plates were incubated at 37°C for 40 min and washed 5 times.
[0104] (4) Add 100 μL of goat anti-rabbit enzyme-labeled secondary antibody (5000-fold dilution), incubate at 37°C for 30 min, wash 5 times, and tap;
[0105] (5) Add color developing solution and develop color for 10 min;
[0106] (6) Add 50 μL of 10% H2SO4 to terminate the reaction and read the OD value at 450 nm using a microplate reader.
[0107] result:
[0108] The standard curve of the indirect competitive ELISA with heterologous coating of sibutramine polyclonal antibody is as follows Figure 4 shown.
[0109] The half inhibitory concentration (IC50) of sibutramine polyclonal antibody against sibutramine 50 ) was 4.89 ng / mL, and the quantitative detection linear range (IC 20 -IC 80 ) was 0.68ng / mL-35.21ng / mL, and the minimum detection limit was 0.21ng / mL.
[0110] In summary, the sibutramine polyclonal antibody provided by the present invention can meet the detection requirements and has good sensitivity, and is a necessary material for establishing a sibutramine immunoassay method.
[0111] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A sibutramine artificial antigen, characterized in that: Obtained by coupling 1-(4-phenol)cyclobutylamine with a carrier protein.
2. The sibutramine artificial antigen according to claim 1, characterized in that: The carrier protein includes at least one of bovine serum albumin and chicken ovalbumin.
3. A method for preparing the sibutramine artificial antigen according to claim 1 or 2, characterized in that: The following steps are involved: The reaction solution of 1-(4-phenol)cyclobutylamine is added to the carrier protein solution, reacted in a dark environment, and then dialyzed to obtain the sibutramine artificial antigen.
4. The preparation method according to claim 3, characterized in that: The preparation method of the reaction solution of 1-(4-phenol)cyclobutylamine comprises the following steps: 1-(4-phenol)cyclobutylamine, 5-hydroxytryptamine, N-carbonylsuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide are dissolved in N,N-dimethylamide respectively, mixed and reacted in a dark environment to obtain the reaction solution of 1-(4-phenol)cyclobutylamine.
5. The preparation method according to claim 3, characterized in that: The preparation method of the carrier protein solution comprises the following steps: The carrier protein is added into the coating buffer to obtain the carrier protein solution.
6. Use of the sibutramine artificial antigen according to claim 1 or 2 in the preparation of sibutramine antibodies.
7. A sibutramine polyclonal antibody, characterized in that: The method is obtained by immunizing an animal with the sibutramine artificial antigen according to claim 1 or 2.
8. Use of the sibutramine polyclonal antibody according to claim 7 in a sibutramine immunoassay method.
9. A sibutramine detection kit, characterized in that: The kit comprises the sibutramine polyclonal antibody according to claim 7.
10. Use of the sibutramine detection kit according to claim 9 in a sibutramine immunoassay method.
Citation Information
Cited By
Electrochemical immunosensor for detecting sibutramine content and sibutramine detection kit
CN120404876A
